PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™
2 Pages
English

PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™ PR Newswire LAWRENCEBURG, Indiana, July 9, 2012 LAWRENCEBURG, Indiana, July 9, 2012 /PRNewswire/ -- PDS Biotechnology Corporation announced today that they have entered into an

Subjects

Informations

Published by
Reads 17
Language English
PDS Biotechnology Corporation Signs
Worldwide Licensing Agreement with Merck
KGaA for Versamune™
PR Newswire
LAWRENCEBURG, Indiana, July 9, 2012
LAWRENCEBURG, Indiana
,
July 9, 2012
/PRNewswire/ -- PDS Biotechnology
Corporation announced today that they have entered into an exclusive
worldwide licensing agreement with Merck KGaA, Darmstadt,
Germany
, for use
of PDS Biotechnology's novel Versamune™ nanotechnology platform in two of
Merck's investigational antigen-specific cancer immunotherapies currently in
pre-clinical development. Merck obtains the rights to utilize the technology with
two investigational antigen-specific cancer immunotherapies which are in pre-
clinical development.
Under the terms of the licensing agreement, PDS Biotechnology Corporation
will receive an undisclosed upfront payment in cash, as well as development
milestone payments, and commercial and sales milestone payments. PDS
Biotechnology Corporation will also receive royalties on sales of the products
incorporating the technology.
Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said,
"We are very pleased that Merck which is experienced in the clinical
development of cancer immunotherapies would like to utilize the Versamune™
technology. For PDS Biotechnology Corporation, this deal is important since the
company's business strategy is focused on a few strategic out-licensing or
partnering deals at a preclinical or early clinical stage. This is the stage where
companies will be seeking to enhance their pipelines by taking advantage of a
new technology that has broad potential applications in clinical research into
the treatment and prevention of cancer and infectious diseases."
About PDS Biotechnology Corporation and Versamune™
PDS Biotechnology Corporation is a privately held biotechnology company
founded to exploit the newly discovered properties of specific synthetic
positively charged (cationic) lipids to commercialize a new generation of
immunotherapies and vaccines. The proprietary Versamune™ platform
nanotechnology, when combined with specific cancer-associated molecules,
has been demonstrated to lead to increased tumor regression rates compared
to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology
Immunotherapy, 2008, 57: (4) 517-530). The Versamune™ nanotechnology
presents a giant step forward in the development of the next generation of
immunotherapies. PDS Biotechnology Corporation's lead products are being
developed to treat prevalent cancers such as cervical cancer, head and neck
cancer and melanoma. The technology is also being applied to the
development of vaccines which are designed to protect against pandemic
diseases. Visit www.pdsbiotech.com for more information on Versamune™ and
products in development.